VRNA (Verona Pharma) Future Price to Earnings

Official company branding of Verona Pharma (VRNA)

The integration of ESG principles into the development of respiratory treatments and ethical manufacturing creates the foundation for David Zaccardi's leadership in product commercialization for Verona Pharma plc (VRNA). The forward P/E multiple for the company on GURU.Markets reflects this process, where 280.80 determines the current status of the parameter. This results in high business scalability, as the mass production of patented inhalers is extremely cost-effective.

veronapharma.com - VRNA Market Cap to Future Earnings Ratio (period 07/04/2022 - 10/18/2025)

Summary analytical data breakdowns for veronapharma.com (VRNA)

- current price and projected stock value:
- business market valuation indicators:
Fundamental valuation:Verona Pharma Corp VRNA
Brand item of Verona Pharma plc

The future of Verona Pharma plc (VRNA) is tied to the success of a single inhaled drug. The forward P/E ratio relates the current share price to projected earnings for the coming period. This metric measures market expectations, making it possible to identify asset overvaluation before an actual decline in revenue occurs. An increase in this indicator signals investor optimism regarding the product's commercialization. By analyzing the expected P/E multiple of Verona Pharma plc (VRNA), one can timely identify the risks of valuation overheating.

Competing companies

Future Price to Earnings haleon.com (HLN)|KVUE (Kenvue Health) - Future Price to Earnings Multiple|Future Price to Earnings Jyong Biotech Limited MENS|Ligand (LGND) - Projected Price to Earnings Ratio|AMRX: Projected Price to Earnings|Perrigo - Market Cap to Future Earnings Ratio|ALVO: Forward P/E Multiple|Liquidia Technologies - Future Price to Earnings Multiple|GLPG (Galapagos N.V.) - Forward P/E Multiple|Projected Price to Earnings Ratio anipharmaceuticals.com ANIP|Future Price to Earnings MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Future Price to Earnings Multiple|Future Price to Earnings Pacira BioSciences, Inc. PCRX|Forward P/E Multiple ARS Corp SPRY|Theravance Biopharma - Forward P/E Multiple|Forward Price to Earnings Multiple Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Future Price to Earnings|Projected Price to Earnings Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - Forward P/E Multiple|Price to Future Earnings Ratio SXTC (China SXT Pharmaceuticals)|Forward P/E Multiple EPRX|Forward P/E Multiple bioharvest.com (BHST)|Future Price to Earnings Invizyne Technologies EXOZ|ORMP: Price to Future Earnings Ratio|ENTX: Projected Price to Earnings|HYFT: Future Price to Earnings|ABVC BioPharma Inc. (ABVC) - Future Price to Earnings|cumberlandpharma.com (CPIX) - Forward P/E Multiple|QNTM (Quantum BioPharma) - Forward P/E Multiple|FGEN: Future Price to Earnings Multiple|Forward P/E Multiple TELO|Forward P/E Multiple Rani Therapeutics Holdings (RANI)|Forward P/E Multiple SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Projected Price to Earnings Ratio|LEXX - Future Price to Earnings|PULM (Pulmatrix) - Price to Future Earnings Ratio|Pheton Holdings Ltd (PTHL) - Future Price to Earnings|Aptorum - Future Price to Earnings Multiple|Projected Price to Earnings LYRA|Projected Price to Earnings Impact BioMedical Inc (IBO)|Forward P/E Multiple TNFA|YCBD: Price to Expected Earnings Ratio|Future Price to Earnings PainReform PRFX|altamiratherapeutics.com (CYTO) - Projected Price to Earnings Ratio|LIPO: Projected Price to Earnings|OPTN (optinose.com) - Price to Future Earnings Ratio|PIRS: Forward P/E Multiple|PROC - Market Cap to Projected Earnings|PTPI (Petros Pharma) - Forward P/E Multiple|Future Price to Earnings QLI|Forward P/E Multiple SLRN|Market Cap to Future Earnings Ratio TFFP